How well are we doing in lipid management?

2010 ◽  
Vol 3 (1) ◽  
Author(s):  
Richard Hobbs
Keyword(s):  
Lipid Management

Patients with Acute Coronary Syndrome are at High Risk Prior to the Event and Lipid Management is Underachieved Pre- and Post- Hospitalization

2018 ◽  
Vol 16 (4) ◽  
pp. 405-413 ◽  
Author(s):  
C. Vlachopoulos ◽  
G. Andrikopoulos ◽  
D. Terentes-Printzios ◽  
S. Tzeis ◽  
E. K. Iliodromitis ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
High Risk ◽  
Lipid Management ◽  
Coronary Syndrome

Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease

2021 ◽  
Vol 77 (24) ◽  
pp. 3016-3027 ◽  
Author(s):  
Connie N. Hess ◽  
Christopher P. Cannon ◽  
Joshua A. Beckman ◽  
Philip P. Goodney ◽  
Manesh R. Patel ◽  
...  
Keyword(s):  
Peripheral Artery Disease ◽  
Blood Lipid ◽  
Peripheral Artery ◽  
Lipid Management ◽  
Artery Disease

scholarly journals Egyptian practical guidance in lipid management 2020

2021 ◽  
Vol 73 (1) ◽  
Author(s):  
Hesham Salah El Din Taha ◽  
Hala Mahfouz Badran ◽  
Hossam Kandil ◽  
Nabil Farag ◽  
Abbas Oraby ◽  
...  
Keyword(s):  
Risk Estimation ◽  
Low Density Lipoprotein ◽  
Management Strategies ◽  
Density Lipoprotein ◽  
Daily Practice ◽  
Main Body ◽  
Atherosclerotic Cardiovascular Disease ◽  
Lipid Management ◽  
Physician Awareness ◽  
User Friendly

Abstract Background Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central objective in the effort to prevent cardiovascular events. Main body Many guidelines were issued by different organizations and societies to define patient risk and establish important recommendations for management strategies. Newer cholesterol-lowering agents (non-statin drugs) are described, and their use is directed primarily to secondary prevention in patients at very high risk of new ASCVD. Conclusion The present guidance summarizes the current methods for risk estimation and outlines the most recent data on lipid management in a simple user-friendly format, to improve physician awareness and help implement guidelines in the daily practice.

scholarly journals Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives

2020 ◽  
Vol 42 ◽  
pp. e59-e64
Author(s):  
Marco Alings ◽  
Olivier Descamps ◽  
Benoit Guillon ◽  
Margret Leosdottir ◽  
Aldo P. Maggioni ◽  
...  
Keyword(s):  
Clinical Practices ◽  
Lipid Management

Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome

2019 ◽  
Vol 36 (12) ◽  
pp. 1643-1651 ◽  
Author(s):  
N. S. R. Lan ◽  
P. G. Fegan ◽  
J. M. Rankin ◽  
D. A. Bell ◽  
G. F. Watts ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Lipid Management ◽  
Coronary Syndrome

Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease

2019 ◽  
Vol 381 (16) ◽  
pp. 1557-1567 ◽  
Author(s):  
Erin D. Michos ◽  
John W. McEvoy ◽  
Roger S. Blumenthal
Keyword(s):  
Cardiovascular Disease ◽  
Atherosclerotic Cardiovascular Disease ◽  
Lipid Management

High prevalence of suboptimal lipid management in the elderly: A call for new treatment guidelines

2015 ◽  
Vol 24 ◽  
pp. S188
Author(s):  
D. Colquhoun ◽  
I. Hamilton-Craig ◽  
K. Kostner ◽  
S. Woodhouse ◽  
M. d’Emden
Keyword(s):  
Treatment Guidelines ◽  
The Elderly ◽  
Lipid Management ◽  
High Prevalence ◽  
New Treatment

Lipid Management with Statins in Type 2 Diabetes Mellitus

2005 ◽  
Vol 39 (10) ◽  
pp. 1714-1719 ◽  
Author(s):  
Brian K Irons ◽  
Lisa A Kroon
Keyword(s):  
Cardiovascular Disease ◽  
Relative Risk ◽  
Risk Reduction ◽  
Relative Risk Reduction ◽  
Data Extraction ◽  
Density Lipoprotein ◽  
Coronary Event ◽  
Lipid Management ◽  
Medline Search ◽  
Patients With Diabetes

OBJECTIVE: To provide an update on lipid management and recent modifications in cholesterol guidelines for use of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), specifically in patients with diabetes. DATA SOURCES: Studies and guidelines were identified through a MEDLINE search (1996–April 2005). STUDY SELECTION AND DATA EXTRACTION: Studies were selected for review if the primary treatment intervention was a statin, at least 4% of the study population held a diagnosis of diabetes, and diabetes subgroup analysis was available. DATA SYNTHESIS: The Heart Protection Study demonstrated an approximately 25% relative risk reduction of a first coronary event in patients with diabetes, a reduction similar to those without diabetes. In subjects with diabetes, a significant reduction in coronary events was noted regardless of the baseline cholesterol level. The Collaborative Atorvastatin Diabetes Study demonstrated a 37% relative risk reduction in the primary prevention of cardiovascular morbidity in patients with diabetes. CONCLUSIONS: Based on the current literature, a low-density lipoprotein cholesterol (LDL-C) level <100 mg/dL remains an appropriate goal for patients with diabetes in the absence of established cardiovascular disease. For higher-risk patients, such as those with diabetes and a history of cardiovascular disease, a more stringent LDL-C goal of <70 mg/dL is an option according to current clinical trial evidence. At least a 30–40% reduction in the LDL-C level is advisable when initiating statin therapy.

Sign in / Sign up

Export Citation Format

Share Document